Business
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"\n DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.\n \n \n \n \n \n \n \n The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of patients with MSA. Dr. Kaufmann will also review ampreloxetine as a potential precision therapy approach in development for nOH in patients with MSA.\n In anticipation of the Phase 3 CYPRESS study topline results in the first quarter of 2026, the event will also provide an overview of the ongoing CYPRESS study of ampreloxetine, and the strategic design choices of the study, informed by the positive results observed in patients with MSA in the REDWOOD study. Additionally, Company management will summarize ampreloxetine's commercial opportunity and strategy.\n A live question and answer session will follow the formal presentations.\n \n About Horacio Kaufmann, MDHoracio Kaufmann, MD is the director of the Dysautonomia Center at NYU Langone. He is dedicated to providing expert care to patients with autonomic disorders. Dr. Kaufmann's approach is grounded in compassion and scientific discovery, ensuring that each patient receives honest answers, hope, and access to cutting-edge clinical trials. His team is committed to transforming lives through a combination of research and medicine. Dr. Kaufmann specializes in diagnosing and treating patients with a range of autonomic disorders, including familial dysautonomia, multiple system atrophy, pure autonomic failure, amyloidosis, and congenital insensitivity to pain. His fascination with the autonomic nervous system, which functions unconsciously and is essential to maintaining every bodily function, has driven his career in neurology and translational research. Throughout his career, Dr. Kaufmann has had the privilege of collaborating with brilliant colleagues, scientists, and physicians, as well as extraordinary families. Together, they have made significant progress in understanding the...